Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% 3-Year EBITDA Growth Rate is 51.90% as of Dec. 2025, which is 36% above its 10-year median of 38.25. The stock has 3 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Verici Dx ranks better than 86.83% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 51.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Verici Dx was 51.90% per year. The lowest was 24.60% per year. And the median was 38.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Verici Dx 3-Year EBITDA Growth Rate Related Terms
VRCDF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Verici Dx's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Verici Dx's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 51.90% mean?
Verici Dx (VRCDF) has a 3-Year EBITDA Growth Rate of 51.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Verici Dx and its competitors. This is 36% above median its historical median of 38.25. Over the past decade, Verici Dx's 3-Year EBITDA Growth Rate has ranged from 24.60 to 51.90. According to the industry distribution chart, Verici Dx ranks #22 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 13.2%.
Is Verici Dx's 3-Year EBITDA Growth Rate too high?
Verici Dx's current 3-Year EBITDA Growth Rate of 51.90% is 36% above median its 10-year median of 38.25. Over the past 10 years, this metric has ranged from a low of 24.60 to a high of 51.90. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Verici Dx's value of 51.90% is 371.8% above this industry median. Based on the distribution chart, Verici Dx ranks #22 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #22 out of 167 companies for 3-Year EBITDA Growth Rate. This places Verici Dx in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. Verici Dx's value of 51.90% is 371.8% above this benchmark. Historically, Verici Dx's own 3-Year EBITDA Growth Rate has ranged from 24.60 to 51.90 over the past decade. While the company's 10-year median is 38.25 vs. the industry median of 11.00, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current 3-Year EBITDA Growth Rate of 51.90% is 371.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current 3-Year EBITDA Growth Rate is 51.90%, which is 36% above median its own 10-year median of 38.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current 3-Year EBITDA Growth Rate of 51.90%. The current 3-Year EBITDA Growth Rate is 51.90%, which is 36% above median its 10-year median of 38.25 and 371.8% above the Medical Diagnostics & Research industry median of 11.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Verici Dx (VRCDF), the current 3-Year EBITDA Growth Rate is 51.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
